Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT03521687
Phase
PHASE4
Status
Completed

Conditions

  • Central Centrifugal Cicatricial Alopecia

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single-center, open-label clinical study to study the efficacy of apremilast in the treatment of mild to moderate central centrifugal cicatricial alopecia. The investigators hypothesize that the anti-inflammatory properties of apremilast may play a role in the decreasing scalp inflammation in patients with CCCA and may prevent further hair loss and potentially induce hair regrowth in patients with mild to moderate disease.

Key Dates

First listed
May 11, 2018
Start date
Nov 15, 2018
Status verified
May 2022
Primary completion
Feb 12, 2021
Completion
Feb 12, 2021

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apremilast
    Patients with CCCA

Primary Outcome Measure

Mean Change in Physician Global Assessment of Improvement (PGA-I) [ Time Frame: Week 0 and Week 24 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mount Sinai West DermatologyNew YorkNew York10023-

Find similar trials in New York, NY

By research site
Mount Sinai West Dermatology· New York, NY

Related Studies